Morgan Stanley Maintains Overweight on IDEXX Laboratories, Raises Price Target to $600
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Erin Wright has maintained an Overweight rating on IDEXX Laboratories (NASDAQ:IDXX) and raised the price target from $590 to $600.
August 04, 2023 | 1:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has maintained an Overweight rating on IDEXX Laboratories and raised the price target from $590 to $600, which could positively impact the stock.
The Overweight rating maintained by Morgan Stanley indicates a positive outlook for IDEXX Laboratories. The increase in the price target from $590 to $600 suggests that the analyst sees further upside potential for the stock, which could lead to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100